Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:06 AM
November 2025
Join Erin Tanner, PA-C for a practical overview of MASLD (metabolic-associated steatotic liver disease) and MetALD, the overlap between metabolic dysfunction and alcohol-related liver injury. Through a real-world case, Erin explains how to interpret FibroScan (kPa/CAP) results, use PEth testing to objectively measure alcohol intake, and recognize how alcohol accelerates fibrosis progression. She reviews risk factors like hypertension, hyperlipidemia, and elevated triglycerides, emphasizing lifestyle interventions, Mediterranean diet, weight loss, and alcohol abstinence to prevent decompensation and liver cancer.
Related Webcast
Webcast: MASLD vs MetALD With Allysa Saggese
September 2025
In this MASLD Community Network session, Allysa Saggese, NP, from Weill Cornell Medicine, New York, walks through a real-world case to demystify the overlap between MASLD, MASH, and metabolic-alcohol related liver disease (MetALD). You’ll learn how to take a precise alcohol history, translate “standard drink” equivalents (≈14 g ethanol), and use objective biomarkers like PEth alongside FIB-4, FibroScan (kPa), ELF, CAP, and MRI elastography to stage disease accurately and catch discordant results. Allysa covers how alcohol can skew labs (ALT/AST, triglycerides, BP), why reducing/abstaining may change non-invasive testing thresholds, when to consider liver biopsy, and who qualifies for HCC surveillance. She also outlines treatment pillars—lifestyle optimization, cardiometabolic risk control, and appropriate pharmacotherapy (including where resmetirom fits and when to avoid it)—so clinicians can tailor care for patients spanning pure MASLD to MetALD. Watch to sharpen your staging, counseling, and monitoring strategy—and help patients make data-driven changes that improve outcomes.
Watch Now
Webcast: MASLD vs MetALD With Anthony Derencius
November 2025
Join Anthony Derencius, PA-C for a concise, case-based update on steatotic liver disease—covering MASLD vs MetALD, how to interpret FibroScan (kPa/CAP), and when to use PEth to objectively quantify alcohol intake. Using a typical patient scenario (ultrasound steatosis, metabolic risk factors, daily wine), Anthony outlines practical steps for risk stratification, lifestyle and alcohol counseling, and monitoring advanced fibrosis, with clear thresholds to distinguish metabolic-predominant from alcohol-associated disease.
Watch Now
Webcast: MASLD vs MetALD With Kelly Smeester
September 2025
In this session from the GHAPP MASLD Community Network, Kelly Smeester, PA-C at South Denver Gastroenterology, reviews a patient case to highlight the overlap between metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction plus alcohol-associated liver disease (MetALD). Using real-world labs, FibroScan values, CAP scores, and the PEth biomarker, she explains how clinicians can distinguish MASLD from MetALD and alcohol-related liver disease. The discussion covers key metabolic risk factors such as PCOS, hypertension, and hyperlipidemia, the impact of moderate alcohol intake, and how these drivers accelerate fibrosis progression and increase the risk of decompensation. Viewers will learn how to evaluate alcohol use through standardized definitions, clinical questionnaires, and biomarkers, as well as best practices for patient education, lifestyle counseling, and management, including diet, exercise, pharmacologic options, and hepatocellular carcinoma (HCC) surveillance. This case-based talk emphasizes why accurate diagnosis and objective assessment of alcohol consumption are essential for both clinical care and research in steatotic liver disease.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Erin Parkinson
July 2025
In this in-depth clinical discussion, Erin Parkinson, NP from the Tampa General Medical Group Transplant Institute, walks through the nuanced process of differentiating stage 3 and stage 4 fibrosis in patients with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Using two illustrative case studies, she explores key clinical signs, lab values, and non-invasive staging tools such as FibroScan, FIB-4, ELF score, and MR elastography. Parkinson discusses the importance of early identification of advanced fibrosis, the reversibility of stage 3 disease, and the implications of a diagnosis of cirrhosis. Erin outlines evidence-based treatment pathways including lifestyle interventions, use of GLP-1 receptor agonists, and initiation of resmetirom (Rezdiffra) for stage 2–3 fibrosis. For cirrhotic patients, the focus shifts to HCC surveillance, screening for clinically significant portal hypertension, and consideration of non-selective beta blockers like carvedilol. This video offers practical insights for hepatology providers navigating the evolving MASLD landscape and highlights how early intervention and accurate staging can impact long-term outcomes.
Watch Now
Live From GHAPP National: Autoimmune Hepatitis: How I Approach It
November 2025
Join Lindsay Yoder, PA-C from Indiana University, for a practical walkthrough on how to evaluate and manage autoimmune hepatitis (AIH). This concise session covers key clinical clues, diagnostic criteria, common patient questions, and real-world approaches to treatment—from steroids and azathioprine to mycophenolate, tacrolimus, and emerging steroid-sparing strategies. Learn how to recognize AIH presentations, set realistic expectations for biochemical remission, manage intolerance and relapse, and tailor long-term therapy for better outcomes. A quick, high-yield guide for clinicians looking to strengthen their approach to autoimmune hepatitis.
Watch Now
Webcast: MASLD vs MetALD With Scott Springer
October 2025
In this educational session, Scott Springer, PA-C, from Erie County Medical Center, discusses the intersection of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MetALD—a condition involving both metabolic dysfunction and alcohol-related liver injury. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk highlights diagnostic challenges, alcohol-use quantification, and the importance of objective biomarkers like PEth testing for accurate classification. Using a real patient case, Scott explains how metabolic risk factors and alcohol intake synergistically accelerate fibrosis, and how clinicians can apply non-invasive tests (FibroScan, ELF, FIB-4) and counseling strategies to improve patient outcomes.
Watch Now
Webcast: Non-Invasive Testing With Tina Gregg
October 2025
In this session, Tina Gregg, NP-C, reviews non-invasive testing (NITs) for MASLD and MASH, using a real-world case to show how to assess risk and stage fibrosis without biopsy. Learn when to use FIB-4, ELF, FibroScan (VCTE), and MR elastography, how to interpret cutoffs, and when to refer to hepatology. Practical takeaways include triaging indeterminate FIB-4 results, recognizing test limitations, and counseling patients on lifestyle and follow-up. Presented via the GHAPP MASLD Community Network.
Watch Now
Webcast: MASLD Basics With Gabriella McCarty
August 2025
In this educational session, Gabriella McCarty, NP-C at Oshi Health, shares practical insights into Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH. Drawing from over 25 years of experience in GI, IBD, and hepatology, she explains how many fatty liver patients are discovered incidentally during workups for unrelated issues such as GERD or routine colonoscopy. Gabriella reviews the new global terminology (MASLD replacing NAFLD, MASH replacing NASH), outlines key metabolic risk factors that define MASLD, and walks through the role of non-invasive tests (FIB-4, FibroScan, ELF, ultrasound) in staging fibrosis. She emphasizes the importance of early detection, patient education, and primary care involvement in identifying at-risk individuals before progression to advanced fibrosis, cirrhosis, or liver cancer. This presentation highlights how MASLD can silently progress, why primary care and GI collaboration are critical, and the growing need for global awareness and prevention of progressive liver disease.
Watch Now
Webcast: MASLD vs MetALD With Tessa Janovsky
September 2025
Tessa Janovsky, PA-C, Arizona Liver Health, delivers a clear, case-based overview of metabolic dysfunction–associated steatotic liver disease (MASLD), MASH, and mixed-etiology MET-ALD. Using a common clinic scenario, she explains how to recognize fatty liver on imaging, why an accurate alcohol history matters, and how non-invasive tools (FibroScan stiffness/CAP and alcohol biomarkers like PEth) guide staging and care. You’ll learn practical, patient-friendly steps—Mediterranean-style nutrition, sustainable weight loss, regular aerobic and resistance exercise, and alcohol cessation—plus when to consider medications, specialist referral, and ongoing surveillance to prevent progression to advanced fibrosis and cirrhosis. Ideal for APPs and GI clinicians seeking straightforward strategies to manage MASLD/MASH in everyday practice.
Watch Now
Live From GHAPP National: MASH Basics
November 2025
In this session, Tessa Janovsky, PA from Arizona Liver Health, provides a clear, practical overview of the basics of MASH and MASLD, including the updated 2023 steatotic liver disease nomenclature, global prevalence trends, and why MASH is a progressive metabolic liver disease that requires early identification. She reviews high-risk populations, the role of primary care and specialty providers, how to use FIB-4 and non-invasive tests to assess fibrosis, and the importance of recognizing rapid progressors. Using a real clinical case, she highlights how to evaluate patients, rule out other etiologies, and optimize metabolic health—including when to consider pharmacotherapy. A concise, clinic-ready primer for clinicians managing MASLD and MASH.
Watch Now